Search results
Results From The WOW.Com Content Network
Mayo v. Prometheus, 566 U.S. 66 (2012), was a case decided by the Supreme Court of the United States that unanimously held that claims directed to a method of giving a drug to a patient, measuring metabolites of that drug, and with a known threshold for efficacy in mind, deciding whether to increase or decrease the dosage of the drug, were not patent-eligible subject matter.
On March 20, 2012, the United States Supreme Court ruled in Mayo Collaborative Services v. Prometheus Laboratories, Inc. [40] that a process patent, which Prometheus Laboratories had obtained for correlations between blood test results and patient health in determining an appropriate dosage of a specific medication for the patient, is not ...
On appeal, the Supreme Court vacated and remanded the case back to the Federal Circuit to reconsider the issues in light of Mayo v. Prometheus. On remand, the Federal Circuit held that Mayo v. Prometheus did not affect the outcome of the case, so the American Civil Liberties Union and the Public Patent Foundation filed a petition for certiorari ...
Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015), [1] is a controversial decision of the US Federal Circuit in which the court applied the Mayo v. . Prometheus test [2] to invalidate on the basis of subject matter eligibility a patent said to "solve ... a very practical problem accessing fetal DNA without creating a major health risk for the unborn chil
The 2011 term of the Supreme Court of the United States began October 3, 2011, and concluded September 30, 2012. The table illustrates which opinion was filed by each justice in each case and which justices joined each opinion.
Unsealed court documents show why he was convicted. In 2020, Donald Trump pardoned a cybersecurity company executive for a secret crime. Unsealed court documents show why he was convicted.
Similar problem arose again in Mayo Collaborative Servs. v. Prometheus Labs., Inc. (2012), where the U.S. Supreme Court majority stated: "The conclusion is that (1) a newly discovered law of nature is itself unpatentable and (2) the application of that newly discovered law is also normally unpatentable if the application merely relies upon ...
In Mayo v. Prometheus in 2012 the Supreme Court unanimously held what the dissenting Justices argued for in this case. [7] That did not lead, however, to invalidation of all drug patents on the grounds that the inventors "merely discovered that certain chemicals interact with the human body in ways directed by chemistry."